<DOC>
	<DOCNO>NCT00773474</DOCNO>
	<brief_summary>A published phase 2 study report lonafarnib administer single agent via continuous intermittent oral dose 76 woman advance breast cancer previously treat chemotherapy and/or endocrine therapy . Objective response rate approximately 10 % observe . This study determine rate progression-free survival patient metastatic breast cancer receive lonafarnib .</brief_summary>
	<brief_title>Lonafarnib Metastatic Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study Patients treat lonafarnib 200 mg PO BID daily day 1-21 every 21-day cycle progression disease , unacceptable toxicity , investigator 's discretion . 1 Cycle = 21 day lonafarnib ( plus time require recover toxicity encounter ) . ECOG Performance Status 0-1 Life Expectancy : Not Specified Hematopoietic : - Platelets &gt; 100 K/mm3 - Absolute Neutrophil Count ( ANC ) &gt; 1.2 K/mm3 - Hemoglobin ≥ 9 g/dl - Serum potassium ≥ 3.3 mmol/L Hepatic : - Aspartate transaminase ( AST ) ≤ 5.0 x ULN - Alanine transaminase ( ALT ) ≤ 5.0 x ULN - Total bilirubin &lt; 1.5 x ULN Renal : - Calculated creatinine clearance ( use Cockcroft-Gault formula ) &gt; 45 cc/min Cardiovascular : - No history Torsades de Pointes , ventricular tachycardia , ventricular fibrillation ventricular flutter</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histological cytological confirm adenocarcinoma breast locally advance metastatic disease . Must able willing enroll companion study entitle `` Predicting Response Toxicity Patients Receiving Lonafarnib Breast Cancer : A Multicenter Genomic , Proteomic Pharmacogenomic Correlative Study : Hoosier Oncology Group COE03 . '' Must measurable disease per RECIST evaluate image within 28 day prior registration protocol therapy . Must willing drink grapefruit juice duration lonafarnib therapy . Previously radiate area ( ) must site disease study entry . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent least 90 day follow completion study treatment . Females childbearing potential must negative pregnancy test within 7 day prior registration protocol therapy . Subjects consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Females must breastfeed . Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year No history radiologic evidence CNS metastases include previously treat , resect asymptomatic brain lesion leptomeningeal involvement ( head CT MRI must obtain within 42 day prior registration protocol therapy ) . No treatment investigational agent within 30 day prior registration protocol therapy . No history Torsades de Pointes , ventricular tachycardia , ventricular fibrillation ventricular flutter . No history syncope . No history seizure . No prolonged QTc interval &gt; 450msec preentry electrocardiogram obtain within 28 day prior registration protocol therapy . No history hypokalemia correct prior registration protocol therapy . No radiation within 14 day prior registration protocol therapy . Patients must recover acute toxic effect prior registration protocol therapy . No prior chemotherapy within 21 day prior registration protocol therapy . No clinically active serious infection judge treat investigator ( CTC v3 , &gt; Grade 2 ) include know human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Following concomitant medication must discontinue 7 day prior registration protocol therapy duration lonafarnib therapy : bisphosphonates , include limited etidronate ( Didronel ) , pamidronate ( Aredia ) , alendronate ( Fosamax ) , risedronate ( Actonel ) , zoledronate ( Zometa Reclast ) , ibandronate ( Boniva ) , ethinylestradiol , gestodene , itraconazole , ketoconazole , cimetidine , erythromycin , carbamazepine , high dose chronic steroid , phenobarbital , phenytoin , rifampin ( rifampicin ) , sulfinpyrazone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>